Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857756 | 0.92 | HPGD (0.44) | HPGDLMNAL3MBTL1MAPTPTGS1 | |
| SCHEMBL18857751 | 0.89 | HPGD (0.40) | HPGDLMNAL3MBTL1MAPTPTGS1 | |
| SCHEMBL18857755 | 0.81 | HPGD (0.44) | HPGDLMNAL3MBTL1MAPTPTGS1 | |
| SCHEMBL18857748 | 0.80 | EGFR (0.41) | L3MBTL1MAPTCA12CA1CA2 | |
| SCHEMBL18857749 | 0.74 | KDM4C (0.43) | L3MBTL1MAPTCA12CA1CA2 | |
| SCHEMBL8241807 | 0.71 | KDM4C (0.53) | LATS1 | |
| SCHEMBL8252207 | 0.71 | MAPT (0.43) | L3MBTL1MAPTLATS1KMT2A | |
| SCHEMBL18857496 | 0.70 | CA12 (0.46) | LMNAL3MBTL1MAPTPTGS1PTGS2 | |
| SCHEMBL18857759 | 0.70 | ECE1 (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13954931 | 0.69 | KDM4C (0.56) | LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | TPAT IP LLC | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | AQP4, PMP22, MAG | HPGD 2560/4885LMNA 1107/4885L3MBTL1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.